[{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cetuximab","moa":"IRS1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kitov Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kitov Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pierre Fabre \/ Not Applicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Merck","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Junshi Biosciences \/ Merck"},{"orgOrder":0,"company":"Menarini","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"MEN1611","moa":"PI3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Menarini \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Menarini \/ Not Applicable"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"NT219","moa":"STAT3 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kitov Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kitov Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Strata Oncology","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Adagrasib","moa":"KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Strata Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Strata Oncology \/ Mirati Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Strata Oncology \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Biodesix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Cetuximab","moa":"HGF","graph1":"Oncology","graph2":"Phase II","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aveo Oncology \/ Biodesix","highestDevelopmentStatusID":"8","companyTruncated":"Aveo Oncology \/ Biodesix"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Monalizumab","moa":"NKG2A","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"BBT-176","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"NKMax","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Autologous natural killer cells","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ NKMax","highestDevelopmentStatusID":"7","companyTruncated":"Merck Group \/ NKMax"},{"orgOrder":0,"company":"Flatiron Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Cetuximab","moa":"ErbB1","graph1":"Oncology","graph2":"Approved","graph3":"Flatiron Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Flatiron Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Flatiron Health \/ Not Applicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Erasca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Erasca","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Erasca"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Pfizer"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Monalizumab","moa":"NKG2A","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cetuximab","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Jacobio Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Peking University Cancer Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cetuximab","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jacobio Pharma \/ Peking University Cancer Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Peking University Cancer Hospital"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"BND-22","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Biond Biologics \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biologics \/ Sanofi"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"OSE-172","moa":"SIRP alpha","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":1.3500000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.3500000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BBT-176","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Aveo Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"HGF IgG1","graph1":"Oncology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ AVEO Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ AVEO Oncology"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BBT-176","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Monalizumab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Innate Pharma \/ Astrazeneca","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pharma \/ Astrazeneca"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cetuximab","moa":"CD47","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Erasca \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Not Applicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"KRAS G12C","graph1":"Oncology","graph2":"Preclinical","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Jacobio Pharma \/ Merck","highestDevelopmentStatusID":"4","companyTruncated":"Jacobio Pharma \/ Merck"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"WEE1","graph1":"Oncology","graph2":"Preclinical","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Zentalis Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"4","companyTruncated":"Zentalis Pharmaceuticals \/ Pfizer"},{"orgOrder":0,"company":"Erasca","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Erasca \/ Pierre Fabre","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Pierre Fabre"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Merck"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Not Applicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hummingbird Bioscience \/ Merck & Co. Inc.","highestDevelopmentStatusID":"4","companyTruncated":"Hummingbird Bioscience \/ Merck & Co. Inc."},{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Enzene Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enzene Biosciences \/ Lupin Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Enzene Biosciences \/ Lupin Ltd"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Innovent Biologics \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Merck Group"},{"orgOrder":0,"company":"Erasca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Erasca \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Not Applicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Foundation Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Foundation Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirati Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Onvansertib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Onvansertib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Quanta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Quanta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"BND-35","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biond Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Biond Biologics \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Biond Biologics \/ Merck Group"},{"orgOrder":0,"company":"Tizona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tizona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tizona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tizona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Onvansertib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Cardiff Oncology \/ TD Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ TD Cowen"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Onvansertib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF V600E","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF V600E","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Tumor Cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Tumor Cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2023","type":"Licensing Agreement","leadProduct":"Hafnium Oxide","moa":"||Tumor Cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ GSK"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2023","type":"Public Offering","leadProduct":"Hafnium Oxide","moa":"||Tumor Cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Jefferies LLC","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Jefferies LLC"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2023","type":"Public Offering","leadProduct":"Hafnium Oxide","moa":"||Tumor Cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Jefferies LLC","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Jefferies LLC"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Tumor Cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for Cetuximab
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
